Lauren Boak
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Journal: Lancet (London, England)
Published: February 02, 2026
Tominersen in Adults with Manifest Huntington's Disease.
Journal: The New England journal of medicine
Published: December 06, 2023
Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies.
Journal: Scientific reports
Published: November 29, 2022
Correction to: Exploring Social Biomarkers in High‑Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross‑Sectional Analysis.
Journal: Journal of autism and developmental disorders
Published: May 06, 2020
Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis.
Journal: Journal of autism and developmental disorders
Published: April 13, 2020
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
Journal: The Journal of clinical psychiatry
Published: July 17, 2018
Cerebral blood flow predicts differential neurotransmitter activity.
Journal: Scientific reports
Published: December 07, 2017
In Search of Biomarkers for Autism Spectrum Disorder.
Journal: Autism research : official journal of the International Society for Autism Research
Published: August 21, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: June 09, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026